A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma.

Trial Profile

A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Rituximab (Primary) ; Bendamustine; Cyclophosphamide; Doxorubicin; Prednisolone; Vincristine
  • Indications Follicular lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RELEVANCE
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 31 Oct 2017 Planned primary completion date changed from 1 May 2017 to 1 Jun 2024.
    • 27 Jul 2017 According to a Celgene Corporation media release, data from this study is expected in the second half of 2017.
    • 28 Dec 2016 Planned primary completion date changed from 1 Apr 2017 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top